Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microplasmin intravitreal injection for exudative age-related macular degeneration with focal vitreomacular adhesion
2008-004844-35Phase 2Completed
- Sponsor
- Oxurion
- Start
- Apr 2009
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ocriplasmin in age-related macular degeneration (AMD) and vitreomacular adhesion (VMA) (2 arms), sponsored by Oxurion. Primary endpoint: Safety Endpoint. Started Apr 2009; status: completed.
02
Drugs
ocriplasmin
03
Conditions
age-related macular degeneration (AMD)vitreomacular adhesion (VMA)
Beyond the preview
Go deeper on 2008-004844-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004844-35.